TerminatedPhase 4

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Stopped: The study was terminated due to low recruitment

Venezuela10 participantsStarted 2006-04

Plain-language summary

This study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 International Units \[IU\]) in anemic patients with solid tumors. The anticipated study duration is 4 months, and the target sample size is 40 individuals.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients with a non-myeloid malignancy * Anemia Exclusion Criteria: * Transfusion of red blood cells within 2 months of study drug * Treatment-resistant hypertension * Acute or chronic bleeding (requiring therapy) within 3 months of study drug

What they're measuring

Hemoglobin Levels at 16 Weeks

Timeframe: 16 Weeks

Trial details

NCT IDNCT02624141

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-12

View on ClinicalTrials.gov More Anemia trials